|
14 Jun 2019 |
UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
|
|
13 Jun 2019 |
Update on Etigilimab (TIGIT) Partnership
|
|
13 Jun 2019 |
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
|
|
13 Jun 2019 |
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
|
|
13 Jun 2019 |
First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma
|
|
13 Jun 2019 |
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
|
|
12 Jun 2019 |
BioInvent publishes first clinical data from BI-1206 Phase l/lla trials
|
|
12 Jun 2019 |
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
|
|
12 Jun 2019 |
New Subcutaneous Formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) Shows Positive Results for the Treatment of Rheumatoid Arthritis (RA) In Data Presented at the Annual European Congress of Rheumatology (EULAR 2019)
|
|
12 Jun 2019 |
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
|
|
11 Jun 2019 |
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
|
|
11 Jun 2019 |
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
|
|
11 Jun 2019 |
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
|
|
10 Jun 2019 |
FDA Grants Genentech’s Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma
|
|
10 Jun 2019 |
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
|
|
10 Jun 2019 |
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
|
|
07 Jun 2019 |
New report about bispecific antibodies engaging T-cells and NK cells
|
|
07 Jun 2019 |
Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
|
|
06 Jun 2019 |
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
|
|
06 Jun 2019 |
Innate pharma enrolls first patient in IPH4102 TELLOMAK phase II study
|
|
06 Jun 2019 |
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
|
|
05 Jun 2019 |
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
|
|
04 Jun 2019 |
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
|
|
04 Jun 2019 |
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
|
|
03 Jun 2019 |
BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody
|
